NDTPOTCHealthcare · Biotechnology

NDT Pharmaceuticals Inc.

$0.51-8.93%($-0.05)

TickerSpark Score

36/100

Weak

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NDTP research report →

52-Week Range23% of range

Low $0.05

Current $0.51

High $2.10

Companywww.ndtpharma.com

NDT Pharmaceuticals Inc., a biotechnology company, focuses on developing various therapies for severe neurological disorders associated with traumatic brain Injury. The company is based in Vienna, Virginia.

CEO: James Hovis
IPO: 2008
HQ: Vienna, VA, US

Price Chart

+618.31% · this period

Valuation

Market Cap: $81.60M
P/E: -3289.99
P/S: 0.00
P/B: 1627.38
EV/EBITDA: -3575.99
Div Yield: 0.00%

Profitability

Gross Margin: 0.00%
Op Margin: 0.00%
Net Margin: 0.00%
ROE: -33.16%
ROIC: -49.47%

Growth & Income

Revenue: $0 · 0.00%
Net Income: $-22,819 · -36.71%
EPS: $0.00 · 300.00%
Op Income: $-22,819
FCF YoY: 0.00%

Performance & Tape

52W High: $2.10
52W Low: $0.05
50D MA: $0.71
200D MA: $0.94
Beta: 0.00
Avg Volume: 4.17K

Get TickerSpark's AI analysis on NDTP

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

Date	Insider	Role	Type	Shares	Value
Mar 29, 07	CARASQUERO FRANCISCO KENT	director, officer: Secretary	other	96,000	$96
Mar 28, 07	CARASQUERO FRANCISCO KENT	director, officer: Secretary	other	0	—
Mar 28, 07	CARASQUERO FRANCISCO KENT	director, officer: Secretary	other	0	—
Jun 2, 06	XINOS JOHN ANASTASIOS	director, officer: President, CFO, Secretary	other	0	—